CLAIM #34036 · Johnson & Johnson (JNJ) · 2025Q2 earnings call · Jul 16, 2025 · due Dec 31, 2030
“We expect to become the #1 oncology company by 2030 with sales of more than $50 billion.”
Joaquin Duato · CEO
PENDING
graded after results covering Dec 31, 2030 are reported
How to check this claim
Look at: Annual oncology segment sales, fiscal year
It came true if: Oncology sales > $50 billion for fiscal year 2030 (and company/analyst-recognized ranking as #1 oncology company by sales)
Where: Company-disclosed segment sales (10-K / annual report / investor day disclosures)
Verify independently
SEC filings for JNJ ↗ · Claim quote is verbatim from the 2025Q2 earnings call.